Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (3)
- Public Health (3)
- Health Services Research (2)
- Advertising and Promotion Management (1)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
-
- Business (1)
- Digestive System Diseases (1)
- Diseases (1)
- Economics (1)
- Endocrinology, Diabetes, and Metabolism (1)
- Equipment and Supplies (1)
- Gastroenterology (1)
- Health Economics (1)
- Health Services Administration (1)
- Marketing (1)
- Oncology (1)
- Public Health Education and Promotion (1)
- Social and Behavioral Sciences (1)
- Institution
- Keyword
-
- Antineoplastic agents (1)
- CADTH (1)
- Chemotherapy (1)
- Colectomy (1)
- Cost analysis (1)
-
- Cost-effectiveness (1)
- Direct to Consumer (1)
- Ethnic disparity (1)
- Health Communication (1)
- Infliximab (1)
- Marketing (1)
- Marketing Spending (1)
- Medication (1)
- Medication Promotion (1)
- Methodological limitations (1)
- PCODR (1)
- Pharmacoeconomic submissions (1)
- Reimbursement (1)
- Systematic review (1)
- Ulcerative colitis (1)
- Publication
- File Type
Articles 1 - 7 of 7
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Pharmacoeconomics Of Metastatic Colorectal Cancer Treatment With Targeted Therapies Guided By Companion Molecular Diagnostics, Luis E. Fernández-Garza, Hector Sánchez-Ibarra, Daniela Treviño-Sáenz, Hugo A. Barrera-Saldaña
Pharmacoeconomics Of Metastatic Colorectal Cancer Treatment With Targeted Therapies Guided By Companion Molecular Diagnostics, Luis E. Fernández-Garza, Hector Sánchez-Ibarra, Daniela Treviño-Sáenz, Hugo A. Barrera-Saldaña
Research Symposium
Background: To guide the treatment with monoclonal antibodies (MAbs) against the epidermal growth factor receptor (EGFR) of metastatic colorectal cancer (mCRC), the FDA recommends prior companion molecular diagnosis (CMDx). It initially recommended screening for mutations in exon 2 of the KRAS gene, and most recently to extend to screening to exons 2, 3, and 4 of KRAS and 2, 3, and 4 of NRAS genes; furthermore, to evaluate the BRAF exon 15 mutation status (including V600E). To date, no studies have been done to compare the cost-benefit of these different CMDXs.
Methods: We have compared the cost of treatment without …
Methodological Challenges In Pharmacoeconomic Submissions For Cancer Drug Reimbursement In Canada From 2019-2021, Nupur Krishnan
Methodological Challenges In Pharmacoeconomic Submissions For Cancer Drug Reimbursement In Canada From 2019-2021, Nupur Krishnan
Undergraduate Student Research Internships Conference
Cancer is the leading cause of death in Canada, carrying a mortality rate of 1 in 4 Canadians. As new therapeutic options are developed, high drug costs place a huge burden on patients and the healthcare system. Due to budget limitations, not all pharmaceuticals can be publicly funded, so difficult decisions must be made for which drugs are funded and in what contexts. The pan-Canadian Oncology Drug Review (pCODR) evaluates submissions for new oncological pharmaceuticals to make reimbursement recommendations. Comprehensive analyses assessing limitations in recent oncology drug submissions have not yet been performed. The objective of this project, therefore, was …
Marketing Channel Effectiveness Of New Medications/Medical Technology, Hadley Mccormick
Marketing Channel Effectiveness Of New Medications/Medical Technology, Hadley Mccormick
Celebration of Learning
This research project will study what marketing platforms/channels are most effective in the dissemination of new medical product news. Many people like myself have an illness/disease that requires daily medication, or require the daily use of a medical device. Due to the increasing influence of Direct to Consumer advertising of pharmaceuticals and the constant development of new medications and devices, patients may now more often go to the doctor with perceptions of what they should do to manage their illness/disease. This study aims to look at how the developers of these medications/medical devices promote their products currently and how certain …
Ethnic And Demographic Differences In Colectomy Rates And Timing For Ulcerative Colitis: 2007-2014, Daniel Bodek, Alana Persaud, Brian Blair, Ahlawat Sushil
Ethnic And Demographic Differences In Colectomy Rates And Timing For Ulcerative Colitis: 2007-2014, Daniel Bodek, Alana Persaud, Brian Blair, Ahlawat Sushil
Rowan-Virtua Research Day
Ulcerative Colitis (UC) is a chronic inflammatory disease of the bowel, with one third of patients requiring a colectomy for fulminant disease and tissue dysplasia. In 2007, infliximab was approved for induction and maintenance of remission in UC, with some evidence to suggest a potential reduction in colectomies. The aim of this study is to examine relative colectomy rates for UC among different ethnicities from 2007 to 2014 in order to evaluate for development of new trends or disparities.
Discrepancies in colectomy rates and timing are seen in our models which mirror closely findings in a prior study from 1999-2003 …
Cost-Effectiveness Analysis Of Enzalutamide, Abiraterone Acetate Plus Prednisone, Cabazitaxel Plus Prednisone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi
Shared Knowledge Conference
Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020. Objective: To conduct a cost-effective analysis of visceral mCRPC therapies post-docetaxel failure from a US healthcare payer perspective utilizing life-time horizon Markov model. These medications received highest National Comprehensive Cancer Network guideline recommendation to treat visceral mCRPC post-docetaxel failure. Methods: A pharmacoeconomic model was …
A Systematic Review Of The Cost-Effectiveness Of Chemotherapy Regimens, Chelsea R. Manion, Eric Blizzard, Emily Bruce, Hannah Chittenden, David Fisher, Lia G. Hickinbotham, Abigail Moon, Nicholas Rudy, Aleda Chen, Kristi Coe
A Systematic Review Of The Cost-Effectiveness Of Chemotherapy Regimens, Chelsea R. Manion, Eric Blizzard, Emily Bruce, Hannah Chittenden, David Fisher, Lia G. Hickinbotham, Abigail Moon, Nicholas Rudy, Aleda Chen, Kristi Coe
The Research and Scholarship Symposium (2013-2019)
Background: The rising cost of chemotherapy dramatically increases the burden on healthcare and presents new challenges in achieving optimal patient outcomes. New treatments, in general, are more specialized but show minor progress in regards to efficacy. Accordingly, the threat of overpaying for chemotherapy regimens has increased. There is a need for a comprehensive review to compile relevant studies in order to inform clinician decisions on the basis of cost-effectiveness and quality of life.
Objectives: The objective of this project is to assess the cost-effectiveness of anticancer medications with a special focus on the quality of life of patients undergoing chemotherapy, …
Recession Proof Pills: An Examination Of The Relationship Between Recession Economics And Pharmaceutical Expenditures, Kevin Gray
Annual Undergraduate Conference on Health and Society
The first decade of the 21st century proved to be a time of turbulence and volatility in the worldwide economy. Oddly enough, even as Americans’ disposable income decreased, spending on health care steadily increased. Americans spent $249.9 billion on prescription drugs in 2009, contrasted against $120.9 billion in 2000—a 105% increase.1 We may question the overall ramifications of such increases in pharmaceutical sales and the correlation to other economic factors. That is, how was the pharmaceutical sector able to boast gains when the housing market collapsed? One answer is that people place a priority on their health, even with limited …